Inclisiran sodium

HistoryInclisiran sodium, brand name Leqvio, is a medicine used to reduce cholesterol in the blood. Inclisiran is being developed by The Medicines Company, a subsidiary of Novartis, which licensed the rights to inclisiran from Alnylam Pharmaceuticals.Inclisiran was approved for use in the European Union in December 2020. In August 2021, it received NICE approval for use by the National Health Service in the UK. In December 2021, it was approved for medical use in the United States. The U.S. Food and Drug Administration considers it to be a first-in-class medication. In August 2023, the National Medical Products Administration approved the use of inclisiran in China.